Pianzaihuang Ointment: What the Approved Label Covers, the Safety Warnings, and the CITES Rule

This article is not medical advice and does not recommend treatment. Pianzaihuang is a genuine, legally protected Chinese medicine with a documented approved indication — and it is also one of the most heavily mythologised products in Chinese pharmacy, promoted online for everything from liver protection to cancer. Both things are true at once, and the only honest way to write about it is to separate the label from the folklore.

If you are buying it from outside China, there is one practical issue that almost no English-language page mentions, and it can stop a shipment at customs. We cover it below.

What it legally is

Pianzaihuang (片仔癀) is a 国家一级中药保护品种 — a Class-I protected Chinese medicinal product, a status the manufacturer dates to 1994. A 2014 Fujian food-and-drug administration document is more specific: “片仔癀是国家一级中药保护品种，处方和工艺均被列为国家绝密级” — both the formula and the manufacturing process are classified at the highest state-secret level.

The legal basis is the 中药品种保护条例 (Regulations on the Protection of Chinese Medicinal Products), promulgated 14 October 1992 and effective 1 January 1993, which prohibits disclosure of composition and process for the duration of the protection period. Only four ingredients are publicly disclosed: 牛黄 (bovis calculus /牛黄), 麝香 (musk), 三七 (notoginseng) and 蛇胆 (snake bile). Their proportions are secret.

Two things the internet gets wrong. First, the popular formula “notoginseng 85%, snake bile 7%, bovis 5%, musk 3%” comes from an overseas journal description, not from any official disclosure. Second, the claim that only 云南白药 and 片仔癀 hold top-secret status is a media formulation; we found no official published list, and different reports include other products. Treat both as unverified.

What the approved label actually says

This is the part that matters, because it is the only claim the manufacturer is legally permitted to make.

Prescription version (国药准字 Z35020243), per the package insert revised 2025-10-01, executed to the 2025 edition of the Chinese Pharmacopoeia:

“清热解毒，凉血化瘀，消肿止痛。用于热毒血瘀所致急慢性病毒性肝炎，痈疽疔疮，无名肿毒，跌打损伤及各种炎症。” — Clears heat and detoxifies, cools the blood and resolves stasis, reduces swelling and relieves pain. Indicated for acute and chronic viral hepatitis, carbuncles and deep-rooted sores, unnamed swellings, traumatic injury and various inflammations attributable to heat-toxin with blood stasis.

Over-the-counter version (same approval number, dual-status product) is narrower: indicated for 痈疽疔疮 and 跌打损伤 — sores and traumatic injury. It drops hepatitis, unnamed swellings and “various inflammations.”

Everything else you will read — liver protection, hangover cure, anti-cancer effect, immunity boosting — is traditional or popular use, not an approved indication. Chinese state media has made precisely this point.

The ointment is a different product

This is the single most important thing for anyone shopping for “Pianzaihuang ointment.”

The regulated product in China is 复方片仔癀软膏 (Compound Pianzaihuang Ointment), a drug with approval number 国药准字 Z35020234, approved 27 May 2015, Class-A OTC, in 5 g and 10 g tubes. Its composition is 片仔癀粉 plus 季德胜蛇药片, and its approved indication is “清热，解毒，止痛。用于痤疮、毛囊炎、带状疱疹、单纯疱疹、脓疱疮” — acne, folliculitis, herpes zoster, herpes simplex and impetigo. It is for external use only and is not to be taken internally; caution in pregnancy.

Two cautions follow. The ointment does not carry the state-secret / Class-I protection status — that applies to the pill and capsule formula and process, not to the ointment. And if a product sold as “Pianzaihuang ointment” carries a 妆字号 (cosmetic) or 消字号 (disinfectant) registration rather than a 国药准字 number, it is not this drug and may not legally claim to treat acne or any other condition. Check the registration number on the tube.

The cosmetics line sold under the Pianzaihuang name is a separate company and a separate regulatory category entirely.

Safety, per the actual insert

• Adverse reactions (post-marketing surveillance): abdominal pain, diarrhoea, indigestion, rash, itching.
• Contraindications: prohibited in pregnancy; prohibited for anyone allergic to the product or its ingredients.
• Caution: people with allergic constitution, and athletes — because the product uses natural musk.

Published case reports in the medical literature are few but real: two cases of acute kidney injury after taking Pianzaihuang (one at four times the dose), with renal function recovering after discontinuation and fluid therapy — heavy metal nephropathy excluded and no aristolochic acid detected (Lin Y-C et al., J Exp Clin Med 2011;3(4):184–186); and one case of drug-induced pneumonitis in a 47-year-old woman with chronic hepatitis, resolving after discontinuation (Kobayashi et al., 1996).

We found no record of substandard heavy-metal or adulteration findings for the pill, and no hepatotoxicity case reports. Note one thing that has been widely misattributed online: the 2022 national cosmetics inspection failure involving a Pianzaihuang-branded toothpaste (bacterial count 7,200 CFU/g against a ≤500 limit) was a cosmetic product from a separate joint-venture entity, not the medicine.

Musk, CITES, and why a shipment can be stopped

The insert states plainly that the product contains natural musk (本品含天然麝香). Musk comes from Moschus deer, and the conservation situation is strict:

• China reclassified musk deer from Class-II to Class-I nationally protected wildlife in 2003, and in 2004 halted wild capture entirely, with stocks of natural musk sealed under standard packaging, annual consumption quota-controlled, restricted to traditional Chinese medicine use, and subject to a special labelling scheme.
• All six Moschus species in China are Class-I protected; the forest musk deer (Moschus berezovskii) is listed Endangered on the IUCN Red List.
• Under CITES, Moschus populations in Afghanistan, Bhutan, India, Myanmar, Nepal and Pakistan are on Appendix I; all other populations on Appendix II.
• Canada’s government states explicitly that musk is CITES-listed and that medicines containing it require the appropriate CITES documentation on entry.
• China’s endangered-species import/export authority has stated that products containing musk cannot be carried out of the country without a permit.

Practical takeaway: if you are ordering Pianzaihuang across a border, or carrying it home, the constraint is wildlife-trade law, not drug law. We could not find any public figure for the manufacturer’s annual natural-musk quota, and we found no FDA import alert, no EU warning, and no TGA or MHRA action against this specific product. Absence of a warning is not approval — but it does mean the “banned in the West” framing that circulates online is not supported.

Price history, and a strange thing happening now

Domestic retail guidance price for the 3 g lozenge, as documented over two decades: ¥110 (1999) → ¥130 (2005) → ¥150 (2007) → ¥200 (2010) → ¥320 (2012) → ¥400 (2014) → ¥500 (2016) → ¥530 (2017) → ¥590 (2020-01-21) → ¥760 (2023-05-05), a rise of ¥170, or 28.8%, the largest single increase on record, with overseas prices up about US$35 per pill.

Then the market turned. During the 2021 speculative wave, the pill traded offline at around ¥1,600; by 2022 buy-back prices had fallen to about ¥400. In October 2025 e-commerce platforms were selling it at ¥588.6–650, more than 20% below the ¥760 official price — an inversion that tells you the speculative premium has come out of the market entirely.

The company behind it, 漳州片仔癀药业 (600436.SH, listed 16 June 2003 at an issue price of ¥8.55), reported 2024 revenue of ¥10.788 billion and net profit attributable to shareholders of ¥2.977 billion, with a market capitalisation around ¥123 billion in January 2025. The first three quarters of 2025 told a different story: revenue ¥7.442 billion, down 11.93%, and net profit ¥2.129 billion, down 20.74%, with market cap around ¥107 billion in late October 2025.

What we could not verify

• Any FDA approval, import alert or warning letter specifically for Pianzaihuang. Not found. Note that the widely cited FDA warning about a product called “Pi Yen Chin” concerns a different product (an eye drop) and should not be conflated.
• Any EU, Australian TGA or UK MHRA warning or seizure of this product. Not found.
• The manufacturer’s annual natural-musk allocation. Not publicly disclosed; the “about 500 kg per year” figure circulating online is unsourced.
• Any official price change after the May 2023 increase. Public reporting still refers to ¥760 as the guidance price.
• The legal status of what overseas sellers are actually shipping. If you buy, verify the 国药准字 number on the package against the manufacturer’s records.

Sources

• Zhangzhou Pianzaihuang Pharmaceutical official package insert, revised 2025-10-01 (zzpzh.com) — composition, approved indications, adverse reactions, contraindications, natural musk statement.
• Fujian FDA document 闽食药监注函〔2014〕208号, 2014-05-27, via HKEX filing — state-secret classification, and confirmation that protection covers the pill/capsule rather than the ointment.
• 中药品种保护条例, 1994-10-14, via ipc.court.gov.cn — protection classes and disclosure prohibition.
• NMPA OTC catalogue, third batch — historical indication wording.
• 复方片仔癀软膏, 国药准字 Z35020234, approved 2015-05-27 — composition, indication, external use only.
• State Forestry and Grassland Administration, 2018 — musk deer Class-I protection, 2004 halt to wild capture, quota and labelling scheme.
• CITES current appendices — Moschus listings; Government of Canada guidance on musk-containing medicines.
• Lin Y-C et al., J Exp Clin Med 2011;3(4):184–186; Kobayashi et al., Nihon Kyobu Shikkan Gakkai Zasshi 1996;34(7):810–815 — adverse event case reports.
• People’s Daily Health client, 2023 — price history; Red Star Capital (163.com), 2025-10-27 — 2025 price inversion; cnfin.com 2025-01-23 and cj.sina.cn 2025-10-28 — company financials.